Meeting
2023 ASCO Annual Meeting
Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype.
Authors
Andrew Yuhas
Iovance Biotherapeutics, Inc., San Carlos, CA
Andrew Yuhas , Joe Dean , Tim Erickson , Marcus Machin , Mohammed Alkhouli , Joe Yglesias , Rafael Cubas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2542)
DOI
10.1200/JCO.2023.41.16_suppl.2542
Abstract #
2542
Poster Bd #
384
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer.
First Author: Takafumi Okayama
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.
First Author: Kavita M. Dhodapkar
Poster
2021 ASCO Annual Meeting
Dysregulation of soluble immune checkpoint proteins in newly-diagnosed early breast cancer patients.
First Author: Bernardo Leon Rapoport
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik